Rafael (RFL) Stock Price, News & Analysis

Company Overview

Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1B clinical studies; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrumentation. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.

Key Stats

• Today's Range: $1.82 to $1.87
• 50-Day Range: $1.65 to $2.16
• 52-Week Range: $1.29 to $2.50
• Volume: 4,029 shs
• Average Volume: 30,172 shs
• Market Capitalization: $46.28 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Rafael Stock Analysis - MarketRank™

Rafael scored higher than 12% of companies evaluated by MarketBeat, and ranked 899th out of 930 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Rafael.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Rafael is -1.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Rafael is -1.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Rafael has a P/B Ratio of 0.53. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.40% of the float of Rafael has been sold short.

Short Interest Ratio / Days to Cover

Rafael has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Rafael has recently increased by 11.59%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Rafael does not currently pay a dividend.

Dividend Growth

Rafael does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.40% of the float of Rafael has been sold short.

Short Interest Ratio / Days to Cover

Rafael has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Rafael has recently increased by 11.59%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.8 / 5
• News Sentiment: 0.20

News Sentiment

Rafael has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 29 news articles for Rafael this week, compared to 20 articles on an average week.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Rafael insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.20% of the stock of Rafael is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 11.30% of the stock of Rafael is held by institutions.

RFL Stock Analysis - Frequently Asked Questions

How have RFL shares performed this year?

Rafael's stock was trading at $1.65 at the beginning of 2025. Since then, RFL stock has increased by 12.1% and is now trading at $1.85.
View the best growth stocks for 2025 here.

How were Rafael's earnings last quarter?

Rafael Holdings, Inc. (NYSE:RFL) issued its earnings results on Wednesday, December, 11th. The company reported ($0.37) earnings per share for the quarter. Rafael had a negative net margin of 5,707.03% and a negative trailing twelve-month return on equity of 53.71%.

Who are Rafael's major shareholders?

Top institutional shareholders of Rafael include Peapod Lane Capital LLC (1.36%), Geode Capital Management LLC (0.71%), Kahn Brothers Group Inc. (0.68%) and Concourse Financial Group Securities Inc..
View institutional ownership trends.

How do I buy shares of Rafael?

Shares of RFL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Rafael own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Rafael investors own include NVIDIA (NVDA), Broadcom (AVGO), CrowdStrike (CRWD), ServiceNow (NOW), Adobe (ADBE), Arista Networks (ANET) and e.l.f. Beauty (ELF).

Company Calendar

• Last Earnings: 12/11/2024
• Today: 3/11/2025
• Next Earnings (Estimated): 3/11/2025
• Fiscal Year End: 7/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Real Estate
• Current Symbol: NYSE:RFL
• CIK: 1713863
• Web: www.rafaelholdings.com
• Phone: (212) 658-1450
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($1.67)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-34,410,000.00
• Net Margins: -5,707.03%
• Pretax Margin: -10,462.27%
• Return on Equity: -53.71%
• Return on Assets: -48.78%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.74
• Quick Ratio: 9.74

Sales & Book Value

• Annual Sales: $697,000.00
• Price / Sales: 66.39
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.51 per share
• Price / Book: 0.53

Miscellaneous

• Outstanding Shares: 25,014,000
• Free Float: 22,157,000
• Market Cap: $46.28 million
• Optionable: Optionable
• Beta: 1.15